RESULTS OF ANNUAL GENERAL MEETING
Paris, France and Cambridge, UK-18 July 2019-Novacyt (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international specialist in clinical diagnostics, today held its Annual General Meeting (AGM), on second convening, following the default of quorum at the first General Meeting dated 19 June 2020, on the same agenda.
In the absence of a quorum for extraordinary resolutions, only ordinary resolutions were voted.
The results of the AGM are set out in the table below, with the Company pleased to announce that all ordinary resolutions proposed to the shareholders were duly passed:
Resolutions | Votes For | Votes Against | Result | ||
Number | % | Number | % | ||
1) Approval of the parent company financial statements for the 2018 financial year | 4,803,930 | 76.7% | 1,461,313 | 23.3% | yes |
2) Approval of the consolidated financial statements for the 2018 financial year | 6,265,296 | 100% | 0 | 0% | yes |
3) Allocation of the result for the 2018 financial year | 6,265,296 | 100% | 0 | 0% | yes |
4) Review of the conventions referred to in article L. 225-38 and following of the French Commercial Code (without the vote of Vatel) | 3,734,387 | 59.6% | 2,530,909 | 41.4% | yes |
5) DischargetotheBoardof Directors | 6,265,296 | 100% | 0 | 0% | yes |
6) Authorisation of the Company to buy back its own shares | 3,734,027 | 59.59% | 2,531,269 | 41.41% | yes |
7) Determination of directors' fees to be allocated to the members of the Board of Directors | 6,264,936 | 99.99% | 360 | 0.01 | yes |
8) Powers for formalities | 6,265,296 | 100% | 0 | 0% | yes |
Number of participating shareholders (by voting form, proxy or present): 41 shareholders representing 6,265,296 shares.
- End-
About Novacyt Group
The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products acrossan extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.
For more information please refer to the website:www.novacyt.com
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)
Jonathan Senior / Fred Walsh / Ben Maddison +44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång +44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell +44 (0)20 3727 1000brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette +33 (0)147 03 69 47 / +33 (0)147 03 69 51arnaud.decheffontaines@fticonsulting.com/astrid.villette@fticonsulting.com
Attachments
- Original document
- Permalink
Disclaimer
Novacyt SA published this content on 30 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2020 08:28:03 UTC